CD274 and neoplasm: To improve the immunosuppressive tumor microenvironment, therefore, an anti-PD-L1 monoclonal antibody was used to block the PD-1/PD-L1 immune checkpoint and reactivate the antitumor killing ability of infiltrated cytotoxic T cells.